We recently published a list of the 12 Best Stocks to Buy in 2025 for Beginners. In this article, we are going to take a look ...

Investors' focus will likely be on the sales performance of ABBV's blockbuster immunology drugs, Rinvoq and Skyrizi, when it ...

AbbVie Inc (NYSE:ABBV)., a leading biopharmaceutical company with a market capitalization of $311.86 billion, has been at the forefront of the industry with its diverse portfolio of pharmaceuticals ...

In last year's update, AbbVie raised the combined 2027 net sales guidance for Skyrizi and Rinvoq by $6 billion to $27 billion ...

AbbVie Inc (NYSE:ABBV)., a leading biopharmaceutical company, stands at a critical juncture as it navigates the loss of ...

AbbVie closed out the year on a high note as its blockbuster biologic Skyrizi once again claimed the top spot in 2024’s final monthly ranking of the biggest TV ad spenders in biopharma.

Skyrizi was the top Rx and over-the-counter (OTC) pharma brand advertising on TV in 2024, according to data released by iSpot.tv on Thursday afternoon. AbbVie’s psoriasis, ulcerative colitis, Crohn’s ...

Previously approved for ulcerative colitis in October 2023, Omvoh (mirikizumab-mrkz) enters an increasingly crowded IBD drug market following the approval of rival IL-23p19 inhibitor Skyrizi ...

Sanofi and Regeneron’s Dupixent, AbbVie’s Skyrizi, Gilead Sciences' Biktarvy and J&J’s Darzalex rounded out the list of top drugs by projected sales this year. Lilly looks to 'protect its ...

A week into its theatrical run, director James Mangold’s A Complete Unknown has passed a neat little milestone at the domestic box office. The music biopic, about the early career of the ...

He has since moved on to leading roles and appears in two contenders this awards season: “Dune: Part Two” and “A Complete Unknown.” Denis Villeneuve’s sequel to “Dune,” which again ...